Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease -April 04, 2024 at 08:00 am EDT

Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug , for clinical development and commercialization, if approvedSabirnetug is the first monoclonal antibody candidate to enter the clinic...

Related Keywords

Switzerland ,New Hampshire ,United States ,Disclaimerof Lonza ,Stefan Egli ,James Doherty ,Acumen Pharmaceuticals ,Capsules Health Ingredients ,Exchange Commission ,Lonza Group Ltd ,Acumen Pharmaceuticals Inc ,Global Head ,Mammalian Biologics ,Chief Development Officer ,Small Molecules ,Looking Statements ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,